{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:29:35Z","timestamp":1776781775643,"version":"3.51.2"},"reference-count":34,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.3892\/etm.2016.3446","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T07:29:08Z","timestamp":1465457348000},"page":"901-908","source":"Crossref","is-referenced-by-count":2,"title":["Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy"],"prefix":"10.3892","volume":"12","author":[{"given":"Xiaomei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingyin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"key20180108133341_b1-etm-0-0-3446","first-page":"222","article-title":"Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?","volume":"61","author":"Wall","year":"2010","journal-title":"Endokrynol Pol"},{"key":"key20180108133341_b2-etm-0-0-3446","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"key":"key20180108133341_b3-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","article-title":"Clinical practice. Graves' disease","volume":"358","author":"Brent","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180108133341_b4-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-38-5-913","article-title":"The use of ACTH and cortisone in the treatment and in the differential diagnosis of malignant exophthalmos","volume":"38","author":"Kinsell","year":"1953","journal-title":"Ann Intern Med"},{"key":"key20180108133341_b5-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","article-title":"Clinical practice. Graves' ophthalmopathy","volume":"360","author":"Bartalena","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180108133341_b6-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"European Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"key20180108133341_b7-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1089\/thy.2000.10.1093","article-title":"Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: Prevalence, natural history and thyrotropin receptor antibody levels","volume":"10","author":"Khoo","year":"2000","journal-title":"Thyroid"},{"key":"key20180108133341_b8-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1089\/thy.1999.9.1175","article-title":"The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy","volume":"9","author":"Khoo","year":"1999","journal-title":"Thyroid"},{"key":"key20180108133341_b9-etm-0-0-3446","first-page":"1222","article-title":"Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy","volume":"83","author":"De","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"key20180108133341_b10-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2249.1993.tb03395.x","article-title":"Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases","volume":"92","author":"Heufelder","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"key20180108133341_b11-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","article-title":"Controversies in the clinical evaluation of active thyroid-associated orbitopathy: Use of a detailed protocol with comparative photographs for objective assessment","volume":"55","author":"Dickinson","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key20180108133341_b12-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"key20180108133341_b13-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.sjopt.2010.10.001","article-title":"Medical management of thyroid eye disease","volume":"25","author":"Yang","year":"2011","journal-title":"Saudi J Ophthalmol"},{"key":"key20180108133341_b14-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","article-title":"Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial","volume":"63","author":"Wakelkamp","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key20180108133341_b15-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/01676831003660663","article-title":"The role of intravenous methylprednisolone immunosuppression in the management of active thyroid eye disease","volume":"29","author":"Tambe","year":"2010","journal-title":"Orbit"},{"key":"key20180108133341_b16-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"key20180108133341_b17-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: Efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key20180108133341_b18-etm-0-0-3446","first-page":"833","article-title":"Therapeutic responses to corticosteroids in Graves' ophthalmopathy","volume":"95","author":"Chang","year":"1996","journal-title":"J Formos Med Assoc"},{"key":"key20180108133341_b19-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9394(02)01970-0","article-title":"Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy","volume":"135","author":"Ohtsuka","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"key20180108133341_b20-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/01676830.2011.603458","article-title":"Optic neuropathy following orbital irradiation for Graves' ophthalmopathy: A case report and literature review","volume":"31","author":"S\u00e1nchez-Orgaz","year":"2012","journal-title":"Orbit"},{"key":"key20180108133341_b21-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/eje.1.02201","article-title":"A questionnaire survey on the management of Graves' orbitopathy in Europe","volume":"155","author":"Perros","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"key20180108133341_b22-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1365-2265.2008.03289.x","article-title":"Latin American Thyroid Society: Management of Graves' orbitopathy in Latin America: An international questionnaire study compared with Europe","volume":"69","author":"Ramos","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key20180108133341_b23-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves' ophthalmopathy: Systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key20180108133341_b24-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11910-012-0256-9","article-title":"Thyroid eye disease: Towards an evidence base for treatment in the 21st century","volume":"12","author":"Gillespie","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"key20180108133341_b25-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.295.6599.634","article-title":"Is endocrine ophthalmopathy related to smoking?","volume":"295","author":"H\u00e4gg","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"key20180108133341_b26-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/BF03350047","article-title":"More on smoking habits and Graves' ophthalmopathy","volume":"12","author":"Bartalena","year":"1989","journal-title":"J Endocrinol Invest"},{"key":"key20180108133341_b27-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180108133341_b28-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","article-title":"Smoking and risk of Graves' disease","volume":"269","author":"Prummel","year":"1993","journal-title":"JAMA"},{"key":"key20180108133341_b29-etm-0-0-3446","first-page":"40","article-title":"Influence of smoking on Graves' disease with or without ophthalmopathy and nontoxic nodular goiter in Taiwan","volume":"93","author":"Chen","year":"1994","journal-title":"J Formos Med Assoc"},{"key":"key20180108133341_b30-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.clinbiochem.2006.11.015","article-title":"Longitudinal course and clinical significance of TGF-beta1, sL- and sE-Selectins and sICAM-1 levels during severe acute stress in children","volume":"40","author":"Briassoulis","year":"2007","journal-title":"Clin Biochem"},{"key":"key20180108133341_b31-etm-0-0-3446","first-page":"181","article-title":"Expression of serum sICAM-1 in patients with primary hepatocellular carcinoma and its relationship with liver fibrosis","volume":"28","author":"Zhou","year":"2012","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"key20180108133341_b32-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejim.2012.10.009","article-title":"Circulating sICAM-1 and sE-Selectin as biomarker of infection and prognosis in patients with systemic inflammatory response syndrome","volume":"24","author":"de Pablo","year":"2013","journal-title":"Eur J Intern Med"},{"key":"key20180108133341_b33-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s10753-013-9615-1","article-title":"Plasma concentration of soluble intercellular adhesion molecule-1 (sICAM-1) is elevated in type 2 diabetic patients, and sICAM-1 synthesis is associated with leptin-induced activation of the mitogen-activated protein kinase (MAPK) pathway","volume":"36","author":"Cha","year":"2013","journal-title":"Inflammation"},{"key":"key20180108133341_b34-etm-0-0-3446","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.thromres.2011.12.004","article-title":"Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients","volume":"129","author":"Dymicka-Piekarska","year":"2012","journal-title":"Thromb Res"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2016.3446\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T23:37:41Z","timestamp":1515454661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2016.3446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,9]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,6,9]]},"published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.3892\/etm.2016.3446"],"URL":"https:\/\/doi.org\/10.3892\/etm.2016.3446","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,9]]}}}